npj Vaccines

Article	Citations
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates	489
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses	269
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action	237
Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2	192
Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic	170
Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases	144
Malaria vaccines since 2000: progress, priorities, products	143
Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19	111
Protein-based antigen presentation platforms for nanoparticle vaccines	107
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents	104
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19	101
Access to and equitable distribution of COVID-19 vaccine in low-income countries	92
COVID-19 vaccines: breaking record times to first-in-human trials	82
The use of viral vectors in vaccine development	77
Extended interval BNT162b2 vaccination enhances peak antibody generation	75
Public attitudes toward COVID-19 vaccination: The role of vaccine attributes, incentives, and misinformation	74
Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel	67
Vaccines for human fungal diseases: close but still a long way to go	66
Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees	65
Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models	60
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy	60
Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines	60
Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein	54
Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice	50
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate	46

Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens	46
Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza	46
A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection	46
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets	45
A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus	45
Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis	45
Design of a broadly reactive Lyme disease vaccine	44
A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge	44
Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination	44
SARS-CoV-2 structural features may explain limited neutralizing-antibody responses	43
Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection	43
Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters	42
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates	42
Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations	40
Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge	39
Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters	39
Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells	38
SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses	37
The future of Japanese encephalitis vaccination: expert recommendations for achieving and maintaining optimal JE control	37
“World in motion” – emulsion adjuvants rising to meet the pandemic challenges	37
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease	36
Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates	35
Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases	35
Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report	35
Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants	34
An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein	34
Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice	33
Current status of monkeypox vaccines	33
The shot, the message, and the messenger: COVID-19 vaccine acceptance in Latin America	32
The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization	32
Is new dengue vaccine efficacy data a relief or cause for concern?	32
Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections	31
Influence of gut microbiota on mucosal IgA antibody response to the polio vaccine	31
Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles	30
A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses	29
ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge	29
Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant	29
Suppression of mucosal Th17 memory responses by acellular pertussis vaccines enhances nasal Bordetella pertussis carriage	29
Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans	28
Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge	28
Universal coronavirus vaccines: the time to start is now	28
Single-administration, thermostable human papillomavirus vaccines prepared with atomic layer deposition technology	27
New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes	27
H7N9 influenza split vaccine with SWE oil-in-water adjuvant greatly enhances cross-reactive humoral immunity and protection against severe pneumonia in ferrets	27
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants	27
Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2	26
Challenges and developments in universal vaccine design against SARS-CoV-2 variants	26
Benefit of COVID-19 vaccination accounting for potential risk compensation	26
A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice	25
Immune response against SARS-CoV-2 variants: the role of neutralization assays	25

A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection	25
Considerations for bioanalytical characterization and batch release of COVID-19 vaccines	25
A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells	25
Promoting versatile vaccine development for emerging pandemics	25
Vaccination as a preventative measure contributing to immune fitness	25
Burkholderia pseudomallei OMVs derived from infection mimicking conditions elicit similar protection to a live-attenuated vaccine	25
Protein engineering strategies for rational immunogen design	25
Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice	24
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability	24
Baseline mapping of severe fever with thrombocytopenia syndrome virology, epidemiology and vaccine research and development	24
The double-sided effects of Mycobacterium Bovis bacillus Calmette–Guérin vaccine	24
Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer	24
Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect	24
Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies	24
KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine	24
Monoclonal antibodies block transmission of genetically diverse Plasmodium falciparum strains to mosquitoes	23
Contagious Bovine and Caprine Pleuropneumonia: a research community’s recommendations for the development of better vaccines	23
Sex-specific effects of aging on humoral immune responses to repeated influenza vaccination in older adults	23
Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines	23
Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation	22
Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults	22
A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection	22
Impact of glycan cloud on the B-cell epitope prediction of SARS-CoV-2 Spike protein	22
The Streptococcus pyogenes vaccine landscape	22
Contributions of lipopolysaccharide and the type IVB secretion system to Coxiella burnetii vaccine efficacy and reactogenicity	22
Navigating facilitated regulatory pathways during a disease X pandemic	22
Is the oral microbiome a source to enhance mucosal immunity against infectious diseases?	21
A chimeric dengue virus vaccine candidate delivered by high density microarray patches protects against infection in mice	21
MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies	21
Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination	21
Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity	21
Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines	21
A protective bivalent vaccine against Rift Valley fever and bluetongue	21
A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial	20
Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination	20
Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination	20
Multicomponent gold nano-glycoconjugate as a highly immunogenic and protective platform against Burkholderia mallei	20
Urgency and necessity of Epstein-Barr virus prophylactic vaccines	20
Sensitivity and breadth of detection of high-throughput sequencing for adventitious virus detection	19
A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19	19
Safety and efficacy of four-segmented Rift Valley fever virus in young sheep, goats and cattle	19
Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice	19
Centrin-deficient Leishmania mexicana confers protection against New World cutaneous leishmaniasis	19
Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge	19
A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine	19
The year that shaped the outcome of the OspA vaccine for human Lyme disease	18
A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection	18
Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2	18
Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19	18
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants	17
An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission	17
Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine	17
The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates	17
Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore	17
Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination	16
Certainty of success: three critical parameters in coronavirus vaccine development	16
Neoantigen cancer vaccine augments anti-CTLA-4 efficacy	16
Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines	16
Rational development of a combined mRNA vaccine against COVID-19 and influenza	16
mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum	16
Force of infection: a determinant of vaccine efficacy?	16
Deimmunization of flagellin for repeated administration as a vaccine adjuvant	16
MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge	16
Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors	16
An alphavirus replicon-based vaccine expressing a stabilized Spike antigen induces protective immunity and prevents transmission of SARS-CoV-2 between cats	16
Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies	16
The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model	16
The rapid progress in COVID vaccine development and implementation	16
Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial	15
A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice	15
Th17-related mammary immunity, but not a high systemic Th1 immune response is associated with protection against E. coli mastitis	15
Model of vaccine efficacy against HSV-2 superinfection of HSV-1 seropositive mice demonstrates protection by antibodies mediating cellular cytotoxicity	15
Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans	15
Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines	15
The HSP70-fused foot-and-mouth disease epitope elicits cellular and humoral immunity and drives broad-spectrum protective efficacy	15
Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2	15
A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars	14
Live-attenuated ME49Δcdpk3 strain of Toxoplasma gondii protects against acute and chronic toxoplasmosis	14
Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine	14
Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques	14

Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant	14
A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern	14
Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses	14
Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2	14
A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform	14
Haplotype-resolved de novo assembly of the Vero cell line genome	14
Pneumococcal capsule blocks protection by immunization with conserved surface proteins	14
Revaccination with Bacille Calmette-Guérin (BCG) is associated with an increased risk of abscess and lymphadenopathy	14
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants	14
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine	14
Vaccination with the recombinant major outer membrane protein elicits long-term protection in mice against vaginal shedding and infertility following a Chlamydia muridarum genital challenge	13
Durable natural killer cell responses after heterologous two-dose Ebola vaccination	13
Correlates of immunity to Group A Streptococcus: a pathway to vaccine development	13
Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders	13
Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets	13
Pandemic-response adenoviral vector and RNA vaccine manufacturing	13
Identification of a neutralizing epitope within minor repeat region of Plasmodium falciparum CS protein	13
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant	13
High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers	13
Sequential immunization induces strong and broad immunity against all four dengue virus serotypes	13
Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic	13
Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique	13
Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern	13
Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development	13
Links between fecal microbiota and the response to vaccination against influenza A virus in pigs	13
Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques	13